Steward Partners Investment Advisory LLC Has $1.94 Million Holding in Celgene Co. (CELG)

Steward Partners Investment Advisory LLC Has $1.94 Million Holding in Celgene Co. (CELG)

Steward Partners Investment Advisory LLC lowered its position in Celgene Co. (NASDAQ:CELG) by 1.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 30,308 shares of the biopharmaceutical company’s stock after selling 597 shares during the period. Steward Partners Investment Advisory LLC’s holdings in Celgene were worth $1,942,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. FMR LLC lifted its position in Celgene by 14.8% in the second quarter. FMR LLC now owns 8,160,001 shares of the biopharmaceutical company’s stock worth $648,067,000 after purchasing an additional 1,051,528 shares during the period. Vident Investment Advisory LLC lifted its position in Celgene by 22.0% in the second quarter. Vident Investment Advisory LLC now owns 9,304 shares of the biopharmaceutical company’s stock worth $739,000 after purchasing an additional 1,677 shares during the period. Marshall Wace LLP lifted its position in Celgene by 304.2% in the second quarter. Marshall Wace LLP now owns 21,261 shares of the biopharmaceutical company’s stock worth $1,689,000 after purchasing an additional 16,001 shares during the period. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp lifted its position in Celgene by 98.8% in the second quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 17,100 shares of the biopharmaceutical company’s stock worth $1,358,000 after purchasing an additional 8,500 shares during the period. Finally, Moneta Group Investment Advisors LLC lifted its position in Celgene by 2,688.6% in the second quarter. Moneta Group Investment Advisors LLC now owns 10,290 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 9,921 shares during the period. 72.71% of the stock is owned by institutional investors and hedge funds.

Shares of Celgene stock traded up $0.44 during trading on Friday, reaching $87.91. The company’s stock had a trading volume of 5,476,876 shares, compared to its average volume of 9,237,553. The company has a quick ratio of 1.99, a current ratio of 2.13 and a debt-to-equity ratio of 4.06. Celgene Co. has a one year low of $58.59 and a one year high of $97.43. The stock has a market capitalization of $61.32 billion, a price-to-earnings ratio of 11.55, a P/E/G ratio of 0.41 and a beta of 1.72.

Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, January 31st. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.32 by $0.07. Celgene had a return on equity of 125.35% and a net margin of 26.48%. The business had revenue of $4.04 billion during the quarter, compared to analysts’ expectations of $3.98 billion. During the same period in the previous year, the business posted $2.00 earnings per share. As a group, sell-side analysts anticipate that Celgene Co. will post 10.01 EPS for the current year.

A number of research analysts have issued reports on the company. Mizuho set a $117.00 price objective on Celgene and gave the company a “buy” rating in a report on Tuesday, October 30th. Cantor Fitzgerald reissued a “buy” rating and set a $100.00 price objective on shares of Celgene in a report on Thursday, January 3rd. BidaskClub raised Celgene from a “strong sell” rating to a “sell” rating in a report on Wednesday, December 5th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Celgene in a report on Thursday, October 25th. Finally, Goldman Sachs Group raised Celgene from a “sell” rating to a “neutral” rating and lifted their price objective for the company from $71.00 to $88.00 in a report on Thursday, January 3rd. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $109.29.

About Celgene

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Further Reading: Understanding each part of a balance sheet

Related posts

Leave a Comment